Printer Friendly

ALEXION NAMES NIH SENIOR INVESTIGATOR TO DIRECTOR OF IMMUNOBIOLOGY POST

 NEW HAVEN, Conn., March 19 /PRNewswire/ -- Alexion Pharmaceuticals, Inc., has appointed Louis Matis, M.D., as director of immunobiology. Dr. Matis, an internationally recognized expert in the biology of T lymphocytes, spent 16 years at the National Institutes of Health.
 "Dr. Matis' background in both basic research and clinical medicine will help us in applying fundamental immunologic principles to the therapy of human diseases," said Leonard Bell, M.D., president of Alexion. "Lou will be a great asset to our team as we move toward the commercialization of our technology."
 At Alexion, Dr. Matis will direct research programs in cell and organ transplantation as well as in autoimmune and inflammatory disease states.
 Prior to joining Alexion, Dr. Matis, 42, was a senior investigator in the laboratory of Molecular Immunoregulation at the National Cancer Institute. In this capacity, Dr. Matis directed studies in the fields of T cell receptor biology, biological response modifiers, and transplant immunology. His tenure at the NIH also included four years as senior investigator in the Center for Biologicals Evaluation and Research, FDA.
 Dr. Matis commented, "The opportunity to apply fundamental discoveries in basic science to therapeutic benefit is enormously appealing. Alexion has the technology and scientific resources to make this possible."
 Dr. Matis has an A.B. degree from Amherst College and an M.D. degree from the University of Pennsylvania School of Medicine. He received his clinical and research training from the University of Chicago and the National Institutes of Health. He is certified by the American Board of Internal Medicine in both General Internal Medicine and Medical Oncology. An author of over 80 scientific publications, Dr. Matis is a member of the American Association of Immunologists and was elected to membership in the American Society for Clinical Investigation.
 Alexion Pharmaceuticals, Inc., based in New Haven, Conn., is a private biopharmaceutical company engaged in the research and development of novel proprietary compounds, cell and gene therapies for treatment of cardiovascular, immunologic, and hematologic disorders.
 -0- 3/19/93
 /CONTACT: Leonard Bell, M.D., president of Alexion Pharmaceuticals, Inc., 203-776-1790; or Anthony J. Russo, Ph.D., of Noonan/Russo Communications, 212-979-9180, for Alexion Pharmaceuticals/


CO: Alexion Pharmaceuticals, Inc. ST: Connecticut IN: MTC SU: PER

WB-OS -- NY031 -- 7888 03/19/93 12:05 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 19, 1993
Words:377
Previous Article:BELL LABS, HARVARD SCIENTISTS GIVE ATOMS A LIGHT TOUCH
Next Article:DUFF & PHELPS RATES DEVELOPMENT AUTHORITY OF BARTOW, BIBB, COWETA AND PUTNAM COUNTIES (GEORGIA POWER COMPANY PROJECTS)
Topics:


Related Articles
ALEXION PHARMACEUTICALS LICENSES GROWTH FACTOR FOR DEVELOPMENT OF TRANSGENIC ANIMALS FROM EMBRYONIC STEM CELLS
ALEXION PHARMACEUTICALS LICENSES PORCINE EMBRYONIC STEM CELLS FOR TRANSGENIC ANIMALS
Alexion MP4 Apogen Treatment For Multiple Sclerosis Reverses Paralysis; Study Results Published in the Journal of Clinical Investigation
Alexion Receives Phase I Small Business Innovation Research Grant Targeting the Treatment of Myocardial Infarction
National Institutes of Health Announce Efficacy of Alexion Pharmaceuticals' Multiple Sclerosis Drug in Primate Model
Alexion Receives Patent Allowance For Class of C5 Inhibitors In Cardiopulmonary Bypass
Yale and Alexion Report Advance in Spinal Cord Repair.
Cardiovascular, Lung, and Blood Immunobiology in Health and Disease.
Cellular Genomics Announces Management Promotions.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters